Clinical Trial

Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 18, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects. The phase 1b portion of the study is designed to assess the safety, tolerability, and PK of TLC-6740 in subjects with obesity, with or without type 2 diabetes mellitus.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2023-04-19; most recent amendment 2025-12-10.
Status change: Not Yet Recruiting → Recruiting 2023-05-04
Trial Details
NCT Number NCT05822544
Lead Sponsor OrsoBio, Inc
Conditions Healthy Subjects, Obesity, Type 2 Diabetes
Enrollment 564 participants
Start Date 2023-04-22
Primary Completion 2026-02 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-18